Cingulate (CINGW) Shares Outstanding (2021 - 2026)
Cingulate's (CINGW) quarterly Shares Outstanding (Entity) came in at $13.9 million in Q2 2026, up 184.19% on a YoY basis from $4.9 million in Q2 2025, and up 174.86% quarter-over-quarter from $5.1 million in Q4 2025.
Analysis
Cingulate (CINGW) Shares Outstanding (2021 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Shares Outstanding (Entity) for 6 consecutive years, with $13.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Shares Outstanding (Entity) rose 184.19% year-over-year to $13.9 million; the trailing twelve-month figure through Jun 2026 stood at $13.9 million (up 184.19% YoY), and the FY2025 full-year result was $5.1 million, up 231.54% from the prior year.
- Shares Outstanding (Entity) rose to $13.9 million in Q2 2026 per CINGW's latest filing, from $5.1 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $13.9 million in Q2 2026 and bottomed at $47121.0 in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $2.3 million across 5 years, with a median of $417522.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Entity) changed 0.0% in 2023, then jumped 2339.42% in 2024.
- Over 5 years, Shares Outstanding (Entity) stood at $47121.0 in 2022, then soared by 60.08% to $75432.0 in 2023, then surged by 1921.42% to $1.5 million in 2024, then soared by 231.54% to $5.1 million in 2025, then surged by 174.86% to $13.9 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $13.9 million, $5.1 million, and $6.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.70 Bn | 623.94 Bn | 17.26 Bn | 2.41 Bn |
| 2 | AbbVie | 441.16 Bn | 434.59 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 266.48 Bn | 258.79 Bn | 11.24 Bn | 1.94 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn | 5.70 Bn |
| 6 | Sanofi | 52.53 Bn | 45.15 Bn | 10.79 Bn | 1.22 Bn |
| 7 | Revolution Medicines | 44.20 Bn | 44.20 Bn | - | 210.89 Mn |
| 8 | Incyte | 25.27 Bn | 20.74 Bn | 1.57 Bn | 200.38 Mn |
| 9 | United Therapeutics | 21.44 Bn | 18.78 Bn | 683.80 Mn | 42.60 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | 13.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 13.19 Mn |
| Dec 31, 2025 | 5.06 Mn |
| Sep 30, 2025 | 5.43 Mn |
| Jun 30, 2025 | 4.39 Mn |
| Mar 31, 2025 | 3.65 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Sep 30, 2024 | 1.77 Mn |
| Jun 30, 2024 | 586,313.00 |
| Mar 31, 2024 | 412,109.00 |
| Dec 31, 2023 | 75,432.00 |
| Sep 30, 2023 | 82,358.00 |
| Jun 30, 2023 | 48,726.00 |
| Mar 31, 2023 | 47,121.00 |
| Dec 31, 2022 | 47,121.00 |
| Sep 30, 2022 | 47,121.00 |
| Jun 30, 2022 | 47,121.00 |
| Mar 31, 2022 | 47,121.00 |
| Dec 31, 2021 | 30,889.00 |